Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

Johann S. de Bono, Niven Mehra, Giorgio V. Scagliotti, Elena Castro, Tanya B. Dorff, Adam Stirling, Arnulf Stenzl, Mark T. Fleming, Celestia S. Higano, Fred Saad, Consuelo Buttigliero, Inge M. van Oort, Alexander Laird, Marielena Mata, Hsiang-Chun Chen, Cynthia G. Healy, Akos Czibere, Karim Fizazi